Please check your internet connection and try again.
# Durveqtix gene therapy
## Overview
Durveqtix (prademagen) is a gene therapy indicated for the treatment of patients with hemophilia B. It is a one-time intravenous infusion that delivers a functional gene to the liver to enable the production of functional factor IX (FIX).
## Primary Indications
Treatment of hemophilia B in adults and pediatric patients aged 12 years and older who have or are at risk of spontaneous bleeding.
## Adult Dosing
**One-time intravenous infusion.** The recommended dose is 5 x 10^12 vector genomes (vg) per kilogram of body weight.
## Pediatric Dosing
**One-time intravenous infusion.** The recommended dose is 5 x 10^12 vector genomes (vg) per kilogram of body weight for patients aged 12 years and older. Dosing for pediatric patients younger than 12 years has not been established.
## Dose Adjustments
No dose adjustments are recommended based on renal or hepatic impairment, as the vector is cleared by the body and does not rely on renal or hepatic metabolism.
## Contraindications
* Known history of severe hypersensitivity to the active substance or any of the excipients.
* Use of concomitant immunosuppressive therapy that could interfere with the gene therapy's efficacy.
## Adverse Effects
The most common adverse reactions reported in clinical trials include:
* Infusion-related reactions (e.g., headache, fatigue, nausea, flushing)
* Elevated liver enzymes (ALT, AST)
* Headache
* Arthralgia
* Nausea
* Dizziness
Serious adverse reactions include anaphylaxis and significant elevation of liver enzymes.
## Key Drug Interactions
* **Immunosuppressants:** Concomitant use of immunosuppressive therapy may reduce the efficacy of Durveqtix. If immunosuppression is necessary (e.g., for organ transplant), carefully consider the potential impact on Durveqtix and discuss with a specialist.
* **Corticosteroids:** May be used to manage infusion-related reactions or immune responses but their use should be carefully managed due to potential impact on gene expression.
## Monitoring
* **Liver Function Tests (LFTs):** Monitor ALT and AST regularly for at least 6 months post-infusion. Elevations may indicate an immune response against the vector or transduced cells.
* **Factor IX Activity:** Monitor FIX levels to assess the efficacy of the treatment.
* **Signs and Symptoms of Hypersensitivity:** Monitor closely during and after infusion for signs of anaphylaxis or other hypersensitivity reactions.
* **Bleeding Events:** Continue to monitor for any new or worsening bleeding episodes.
## Clinical Pearls
* Durveqtix is a one-time treatment.
* Patients should be monitored closely for immune responses, particularly elevations in liver enzymes, which may require corticosteroid treatment.
* The long-term durability and safety profile are still being evaluated.
* It is crucial to administer Durveqtix in a specialized treatment center with experience in gene therapy and hemophilia management.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and relevant guidelines for the most up-to-date and complete details regarding drug use.
